Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer

DISEASE CHARACTERISTICS:

Histologically confirmed infiltrating carcinoma of the breast meeting any of the following criteria:

T1-3, any N disease
Proven ductal carcinoma in situ

Unresected disease

Planned mastectomy as definitive surgical procedure

Known or suspected metastatic disease allowed provided mastectomy is planned
Nonpalpable tumor allowed (e.g., initial T2-3 tumor that responded to preoperative therapy)
No inflammatory breast cancer or other T4 features

Successful baseline ductogram

Baseline nipple aspiration procedure must identify a duct productive of nipple aspirate fluid
No severe nipple retraction
Hormone receptor status not specified

PATIENT CHARACTERISTICS:

Female patients
Menopausal status not specified
ECOG performance status 0-2
Absolute neutrophil count ≥1,500/mm^3
Platelet count ≥ 100,000/mm^3
Hemoglobin ≥ 9.0 g/dL
Creatinine ≤ 2 times upper limit of normal (ULN)
Bilirubin ≤ 2 times ULN
AST and ALT ≤ 2.5 times ULN
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No significant history of severe allergy to iodinated contrast material or debilitating anxiety that may not allow for a ductogram

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
Prior preoperative chemotherapy, trastuzumab (Herceptin®), or hormonal therapy allowed provided it was completed 7-14 days prior to study treatment
No prior radiation therapy, excisional biopsy, breast reduction, areolar surgery, or breast implant (present or past history of implant that was removed)
No other prior procedure that may have altered the breast ductal system in the ipsilateral breast
No other concurrent chemotherapy, radiotherapy, endocrine therapy, or biologic agents for breast cancer
No other concurrent investigational drugs
Concurrent bisphosphonates allowed